Ascribe Bio announced a strategic research and development collaboration with Corteva aimed at advancing its novel biofungicide technology for seed treatment applications. The multi-year project will evaluate how Ascribe?s ascaroside technology, currently being commercialized in Phytalix products for foliar applications, can help protect seedlings from early-season fungal diseases. Seed-applied biofungicides are a growing part of this market as farmers continue to seek new, innovative options for targeted disease control.
Phytalix is based on natural small molecules known as ascarosides, some of which can prime pathogen resistance pathways in plants. By applying these products directly to the seed, the partners aim to protect germinating seeds from soil borne pathogens and help seedlings develop stronger roots and better withstand early season disease and stress pressure. Under the agreement, Ascribe will lead core R&D work, including lab studies and early field trials.
Corteva will contribute formulation expertise, seed treatment capabilities, and agronomic testing across key growing regions.
